Plasma lecithin:cholesterol acyltransferase activity modifies the inverse relationship of C-reactive protein with HDL cholesterol in nondiabetic men

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1801, Issue 1, 2010, Pages 84-88

  Dullaart, R P F ^a   Perton, F ^a   Kappelle, P J W H ^a   de Vries, R ^a   Sluiter, W J ^a   van Tol, A ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Apolipoprotein A I; High density lipoprotein cholesterol; High sensitivity C reactive protein; Lecithin:cholesterol acyltransferase activity

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TRIACYLGLYCEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; ENZYME ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

AGE FACTORS; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; HUMANS; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; SMOKING;

EID: 71549156245     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2009.09.019     Document Type: Article

References (52)

1. Vega G.L., and Grundy S.M. Hypoalphalipoproteinemia (low high density lipoprotein cholesterol) as a risk factor for coronary heart disease. Curr. Opin. Lipidol. 7 (1996) 209-216
2. Prospective Studies Collaboration, Lewington S., Whitlock G., Clarke R., Sherliker P., Emberson J., Halsey J., Qizilbash N., Peto R., and Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370 (2007) 1829-1839
3. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., Kastelein J.J., Bittner V., Fruchart J.C., and Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357 (2007) 1301-1310
4. von Eckardstein A., Schulte H., and Assmann G. Increased risk of myocardial infarction in men with both hypertriglyceridemia and elevated HDL cholesterol. Circulation 99 (1999) 1925
5. Corsetti J.P., Zareba W., Moss A.J., Rainwater D.L., and Sparks C.E. Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis 187 (2006) 191-197
6. van der Steeg W.A., Holme I., Boekholdt M., Larsen M.L., Lindahl C., Stroes E.S., Tikkanen M.J., Wareham N.J., Faergeman O., Olsson A.G., Pedersen T.R., Khaw K.T., and Kastelein J.J. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular disease. J. Am. Coll. Cardiol. 51 2008 (2008) 634-642
7. Kontush A., and Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58 (2006) 342-374
8. Singh I.M., Shishehbor M.H., and Ansell B.J. High-density lipoproteins a therapeutic target. JAMA 298 (2007) 786-798
9. Feng H., and Li X.A. Dysfunctional high-density lipoprotein. Curr. Opin. Endocrinol. Diabetes Obes. 16 (2009) 156-162
10. Borggreve S.E., de Vries R., and Dullaart R.P.F. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur. J. Clin. Invest. 33 (2003) 1051-1069
11. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342 (2000) 836-843
12. Saito M., Ishimitsu T., Minami J., Ono H., Ohrui M., and Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 167 (2003) 73-79
13. Dullaart R.P.F., de Vries R., Dikkeschei L.D., and Sluiter W.J. Higher plasma leptin largely explains increased C-reactive protein levels in women. Eur. J. Clin. Invest. 37 (2007) 231-233
14. Dullaart R.P.F., de Vries R., Sluiter W.J., and Voorbij H.A. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus. Clin. Endocrinol. 70 (2009) 221-226
15. Glomset J.A., and Wright J.L. Some properties of a cholesterol esterifying enzyme in human plasma. Biochim. Biophys. Acta 89 (1964) 266-276
16. Santamarina-Fojo S., Lambert G., Hoeg J.M., and Brewer H.B. Lecithin:cholesterol acyltransferase: role in lipoprotein cholesterol transport and atherosclerosis. Curr. Opin. Lipidol. 11 (2000) 267-275
17. Czarnecka H., and Yokoyama S. Regulation of cellular cholesterol efflux by lecithin:cholesterol acyltransferase reaction through nonspecific lipid exchange. J. Biol. Chem. 271 (1996) 2023-2028
18. Matsuura F., Wang N., Chen X.C., and Tall A.R. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apo E- and ABCG1-dependent pathway. J. Clin. Invest. 116 (2006) 144-1435
19. Rousset X., Vaisman B., Amar M., Sethi A.A., and Remaley A.T. Lecithin:cholesterol acyltransferase-from biochemistry to role in cardiovascular disease. Curr. Opin. Endocrinol. Diabetes Obes. 16 (2009) 163-171
20. Calabresi L., Baldassarre D., Castelnuovo S., Conca P., Bocchi L., Candini C., Frigerio B., Amato M., Sirtori C.R., Alessandrini P., Arca M., Boscutti G., Cattin L., Gesualdo L., Sampietro T., Vaudo G., Veglia F., Calandra S., and Franceschini G. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Atherosclerosis 204 (2009) 141-146
21. Tanigawa H., Billheimer J.T., Tohyama J., Fuki I.V., Ng D.S., Rothblat G.H., and Rader D.J. Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation 120 (2009) 160-169
22. Vohl M.C., Neville A.M., Kumarathasan R., Braschi S., and Sparks D.L. A novel lecithin:cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation. Biochemistry 38 (1999) 6976-6981
23. Murakami Y., Kamiyama S., Howlader Z.H., Yamato T., Komai M., and Furukawa Y. Lecithin:cholesterol acyltransferase is insufficient to prevent oxidative modification of low-density lipoprotein. J. Biochem. 131 (2002) 17-19
24. McPherson P.A., Young I.S., and McEneny J. A dual role for lecithin:cholesterol acyltransferase (EC 2.3.1.43) on lipoprotein oxidation. Free Radic. Biol. Med. 43 (2007) 1484-1493
25. Ayyobi A.F., McGladdary S.H., Chan S., Mancini G.B.J., Hill J.S., and Frohlich J.J. Lecithin:cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis 177 (2004) 36-361
26. Hovingh G.K., Hutten B.A., Holleboom A.G., Petersen W., Rol P., Stalenhoef A., Zwinderman A.H., de Groot E., Kastelein J.J.P., and Kuivenhoven J.A. Compromised LCAT function is associated with increased atherosclerosis. Circulation 112 (2005) 879-884
27. Frohlich J., and Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin. Chem. 49 (2003) 1873-1880
28. Dullaart R.P.F., Sluiter W.J., Dikkeschei L.D., Hoogenberg K., and van Tol A. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur. J. Clin. Invest. 24 (1994) 188-194
29. Albers J.J., Chen C.H., and Adolphson J.L. Lecithin:cholesterol acyltransferase (LCAT) mass; its relationship to LCAT activity and cholesterol esterification rate. J. Lipid. Res. 22 (1981) 1206-1213
30. Florén C.H., Chen C.H., Franzen J., and Albers J.J. Lecithin:cholesterol acyltransferase in liver disease. Scand. J. Clin. Lab. Invest. 47 (1987) 613-617
31. Dullaart R.P.F., Perton F., Sluiter W.J., de Vries R., and van Tol A. Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. J. Clin. Endocrinol. Metab. 93 (2008) 4860-4866
32. R.P.F. Dullaart, F. Perton, M.M. van der Klauw, H.L. Hillege, W.J. Sluiter, on behalf of the PREVEND Study Group. High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis (in press) [Electronic publication ahead print]; doi:10.1016/j.atherosclerosis.2009.07.42.
33. A.G. Holleboom, J.A. Kuivenhoven, M. Vergeer, G.K. Hovingh, J.N. van Miert, N.J. Wareham, J.J. Kastelein, K.T. Khaw, S.M. Boekholdt, Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women-a prospective case-control analysis nested in the EPIC-Norfolk population study. J. Lipid Res. (in press) [Electronic publication ahead of print]; doi:10.1194/P900038-JLR200.
34. Barlage S., Fröhlich D., Böttcher A., Jauhiainen M., Müller H.P., Noetzel F., Rothe G., Schütt C., Linke R.P., Lackner K.J., Ehnholm C., and Schmitz G. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J. Lipid. Res. 42 (2001) 281-290
35. Levels J.H., Pajkrt D., Schultz M., Hoek F.J., van Tol A., Meijers J.C., and van Deventer S.J. Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim. Biophys. Acta 1771 (2007) 1429-1438
36. McConnell J.P., Branum E.L., Ballman K.V., Lagerstedt S.A., Katzmann J.A., and Jaffe A.S. Gender differences in C-reactive protein concentrations-confirmation with two sensitive methods. Clin. Chem. Lab. Med. 40 (2002) 56-59
37. Jones D.Y., Judd J.T., Taylor P.R., Campbell W.S., and Nair P.P. Menstrual cycle effect on plasma lipids. Metabolism 37 (1988) 1-2
38. World Health Organization. Expert Committee on diabetes mellitus: definition, diagnosis, and classification of Diabetes Mellitus and its complications. Report WHO 1999.
39. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto Jr. A.M., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J., and JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New. Engl. J. Med. 359 (2008) 2195-2207
40. Bonnet J., McPherson R., Tedgui A., Simoneau D., Nozza A., Martineau P., Davignon J., and CAP Investigators. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin. Ther. 30 (2008) 2298-2313
41. Warnick G.R., Nauck M., and Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogenous assays. Clin. Chem. 47 (2001) 1579-1596
42. Steinmetz J., Tarallo P., Fournier B., Caces E., and Siest G. Reference limits of apolipoprotein A-I and apolipoprotein B using an IFCC standardized immunonephelometric method. Eur. J. Clin. Chem. Clin. Biochem. 33 (1995) 337-342
43. Bérard A.M., Föger B., Remaley A., Shamburek R., Vaisman B.L., Talley G., Paigen B., Hoyt Jr. R.F., Marcovina S., Brewer Jr. H.B., and Santamarina-Fojo S. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat. Med. 3 (1997) 744-749
44. Hoeg J.M., Santamarina-Fojo S., Bérard A.M., Cornhill J.F., Herderick E.E., Feldman S.H., Haudenschild C.C., Vaisman B.L., Hoyt Jr. R.F., Demosky Jr. S.J., Kauffman R.D., Hazel C.M., Marcovina S.M., and Brewer H.B. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 11448-11553
45. Nyström T. C-reactive protein: a marker or player. Clin. Sci. 113 (2007) 79-81
46. B.G. Nordestgaard, J. Zacho. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr. Metab. Cardiovasc. Dis. 28 (2009) 521-524.
47. Elliott P., Chambers J.C., Zhang W., Clarke R., Hopewell J.C., Peden J.F., Erdmann J., Braund P., Engert J.C., Bennett D., Coin L., Ashby D., Tzoulaki I., Brown I.J., Mt-Isa S., McCarthy M.I., Peltonen L., Freimer N.B., Farrall M., Ruokonen A., Hamsten A., Lim N., Froguel P., Waterworth D.M., Vollenweider P., Waeber G., Jarvelin M.R., Mooser V., Scott J., Hall A.S., Schunkert H., Anand S.S., Collins R., Samani N.J., Watkins H., and Kooner J.S. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302 (2009) 37-48
48. Skretting G., Gjernes E., and Prydz H. Regulation of lecithin:cholesterol acyltransferase by TGF-beta and interleukin-6. Biochim. Biophys. Acta 1255 (1995) 267-272
49. Kontush A., de Faria E.C., Chantepie S., and Chapman M.J. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 526-533
50. Nobecourt E., Davies M.J., Brown B.E., Curtiss L.K., Bonnet D.J., Charlton F., Januszewski A.S., Jenkins A.J., Barter P.J., and Rye K.A. The impact of glycation of apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 50 (2007) 643-653
51. Nakhjavani M., Esteghamati A., Esfahanian F., Ghanei A., Rashidi A., and Hashemi S. HbA1c negatively correlates with LCAT activity in type 2 diabetes. Diab. Res. Clin. Pract. 81 (2008) 38-41
52. Riemens S.C., van Tol A., Sluiter W., and Dullaart R.P.F. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 140 (1998) 71-79